Tectonic Therapeutic (TECX) Net Income towards Common Stockholders (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$25.2 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$25.2 million, down 58.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$83.5 million (down 42.3% YoY), and the FY2025 annual result was -$74.2 million, down 27.89% from the prior year.
• Net Income towards Common Stockholders fell to -$25.2 million in Q1 2026 per TECX's latest filing, from -$19.2 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $67.5 million in Q2 2023 and troughed at -$29.8 million in Q1 2022.
• A 5-year average of -$14.0 million and a median of -$19.0 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders surged 340.52% in 2023, then tumbled 118.78% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$25.0 million in 2022, then jumped by 68.57% to -$7.9 million in 2023, then sank by 57.24% to -$12.4 million in 2024, then slumped by 55.39% to -$19.2 million in 2025, then sank by 31.29% to -$25.2 million in 2026.
• Business Quant data shows TECX's Net Income towards Common Stockholders at -$25.2 million in Q1 2026, -$19.2 million in Q4 2025, and -$19.0 million in Q3 2025.